Table 1 Patient characteristics (n = 50)
From: Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer
|  | No. Patients (n = 50) |
|---|---|
Age, median (range), yr | 57 (32–80) |
Follow-up period (m) | 59.1 (2–120) |
FIGO | |
 Stage I | 25 (50%) |
 Stage II | 4 (8%) |
 Stage III | 12 (24%) |
 Stage IV | 9 (18%) |
Histology | |
 High-grade serous | 16 (30%) |
 Endometrioid | 12 (8%) |
 Clear cell | 22 (44%) |
Dissemination and metastasis at diagnosis (overlapped, depending on the cases) | |
 Dissemination | 18 (36%) |
 Lymph node metastasis | 12 (24%) |
 Distant metastasis | 3 (0.6%) |
Recurrent site (overlapped, depending on the cases) | |
 Dissemination | 17 (34%) |
 Lymph node metastasis | 10 (20%) |
 Distant metastasis | 6 (12%) |
Par3 expression | |
 High | 10 (20%) |
 Intermediate | 10 (20%) |
 Low | 30 (60%) |